por
Brendon Nafziger, DOTmed News Associate Editor | November 09, 2010
Drug maker Eli Lilly and Company said Monday it had struck a deal to buy a biotech start-up that's developing an imaging agent that could help diagnose Alzheimer's disease.
Indianapolis, Ind.-based Eli Lilly said it plans to buy Avid Radiopharmaceuticals with an upfront payment of $300 million, and then $500 million contingent upon regulatory and commercial milestones for the imaging agent, called florbetapir F 18.
Six-year-old Avid's employees will remain in their Philadelphia headquarters after the purchase, Eli Lilly said, under the guidance of founder Dr. Daniel M. Skovronsky, a neuropathologist who trained at the University of Pennsylvania.
Ad Statistics
Times Displayed: 48800
Times Visited: 1523 Keep biomedical devices ready to go, so care teams can be ready to care for patients. GE HealthCare’s ReadySee™ helps overcome frustrations due to lack of network and device visibility, manual troubleshooting, and downtime.
Florbetapir F18 is currently in clinical trials to see how well it enables PET scans to pick up beta-amyloid plaque deposits in living patients, in order to give earlier, more definitive, Alzheimer's diagnoses.
Florbetapir is one of a
handful of radiopharmaceuticals under investigation to improve Alzheimer's diagnoses. Bayer HealthCare is researching florabetaben, and GE Healtchare is looking into GE-067.
